Imatinib mesylate is a tyrosine kinase inhibitor used primarily in the treatment of leukemia. Chronic Myeloid Leukemia (CML) cells contain a hybrid tyrosine kinase BCR/ABL that works to provide the cancer cell with ATP at an uncontrolled rate. Imatinib mesylate inhbiits this hybrid protein to slow cell growth and promote apoptosis.
| Mechanism of Action | Imatinib mesylate binds to the ATP binding site of the BCR/ABL tyrosine kinase and stabilizes its inactive form. |
| Molecular Formula | C29H31N7O•CH3SO3H |
| References | Goldman, J. M., & Melo, J. V. (2003). Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment. New England Journal of Medicine, 349(15), 1451-1464. doi:10.1056/nejmra020777 Marcucci, G., Perrotti, D., & Caligiuri, M. A. (2003, April 1). Understanding the Molecular Basis of Imatinib Mesylate Therapy in Chronic Myelogenous Leukemia and the Related Mechanisms of Resistance. Clinical Cancer Research, 9(4), 1248-1252. Retrieved from http://clincancerres.aacrjournals.org/content/9/4/1248 |
